(Q38439813)

English

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

scientific article published on 24 April 2015

Statements

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis (English)
Christina Howlett
Daniel J Landsburg
Stephen J Schuster
Sunita Dwivedy Nasta

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit